(Medical Xpress) -- Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related ...
May 11, 2011
0
0
Colorectal cancer is a common lethal disease, and treatment decisions are increasingly influenced by which genes are mutated within each patient. Some patients with a certain gene mutation benefit from a chemotherapy drug ...
Sep 24, 2019
0
113
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...
Oct 17, 2017
0
5
(Medical Xpress)—A unique sub-type of bowel cancer has been discovered which has a worse outcome than other types of colon cancer and is resistant to certain targeted treatments, according to research published today in ...
Apr 15, 2013
0
0
Mutations in a gene called KRAS are causally associated with acquired resistance to targeted therapies for colorectal cancers (CRC), according to new findings from EU-funded researchers from Italy and their research colleagues ...
Jun 25, 2012
0
0
New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.
Jun 1, 2012
0
0
Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug. Jamming those circuits with ...
Sep 7, 2011
0
0
The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional ...
Oct 24, 2022
0
6
(HealthDay)—Increasing adherence to evidence-based prophylaxis protocols for epidermal growth factor receptor inhibitor (EGFRi)-associated rash can reduce interventions and toxicity-associated chemotherapy interruptions, ...
Jul 13, 2020
0
0
Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.
Jul 8, 2019
0
0
Cetuximab (IMC-C225—marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer.
This text uses material from Wikipedia, licensed under CC BY-SA
